An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting the ...

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...

Acromegaly is a rare but serious hormonal disorder caused by excess growth hormone, usually due to a benign tumour in the pituitary gland. It typically develops in adulthood and leads to noticeable ...

Gigantism and acromegaly are growth disorders that result from excess amounts of growth hormone in the body. The conditions are similar but have several differences. Growth hormone is one of the ...

Please provide your email address to receive an email when new articles are posted on . Fifty-four percent of adults with acromegaly receiving pasireotide reached an IGF-I level less than or equal to ...

Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide ...

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego ...

A 23-year-old man was admitted to the hospital with severe dyspnoea, elevated body temperature, and rhinorrhoea. Several endocrinological disorders were known in the patient’s family. Echocardiography ...